Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer

Since the introduction of targeted therapies (TTs) for metastatic renal cell cancer (mRCC) in 2005, a limited amount of epidemiological data on efficacy of modern drug therapies for synchronous mRCC has been published. We present a comprehensive nationwide cohort including all cases of primarily met...

Descripción completa

Detalles Bibliográficos
Autores principales: Laru, Lauri, Ronkainen, Hanna, Vaarala, Markku H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378950/
https://www.ncbi.nlm.nih.gov/pubmed/34422411
http://dx.doi.org/10.1155/2021/5237695

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378950/
https://www.ncbi.nlm.nih.gov/pubmed/34422411
http://dx.doi.org/10.1155/2021/5237695

Ejemplares similares